Publication: 136

Publication: 136

Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia – Cancer and leukemia group B study 10107

PubMed

PMC

QxMD

DOI

Google Scholar

Citation:: Leuk Lymphoma vol 49 (7) 1274-1278

Year:: 2008
Type:: Manuscript
Funding:: NCTN
Endpoint:: Primary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: pmc-release

Note:

Methodological:: No
Biospecimen:: No
SDC:: No
Book Volume:

Parents:: None
Children:: None

Program:: OGC
Primary Committee:: Leukemia
Sec. Committees:

Pharmas:
Grants:: U10 CA032291, CA33601, CA101140, U10 CA077658, CA02599, CA32291, CA41287, CA03927, U10 CA031946, U10 CA033601, U10 CA101140, U10 CA041287, CA77658, CA37135, CA31946, U10 CA003927, CA07968

Corr. Author:
Authors:: Meir Wetzler Kathleen A. Donohue Olatoyosi M. Odenike Eric J. Feldman David D. Hurd Richard M. Stone Peter Westerfelt Clara D. Bloomfield Richard A. Larson

Networks:

Study: CALGB-10107
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 2

Keywords:: Chronic myeloid leukemia, imatinib mesylate, resistance, oblimersen, bcl-2